Humodar B 100 is a recombinant human insulin product used to help manage diabetes mellitus in patients who require replacement therapy. It is applied to address high blood sugar levels (hyperglycemia) associated with diabetes mellitus. As a human insulin preparation, it is utilized to help maintain appropriate blood sugar levels.

This medication is commonly used to treat Type 1 and Type 2 diabetes by providing the long-acting background coverage needed to keep blood sugar levels stable throughout the day and overnight. In clinical scenarios, it is relevant when chronic high glucose creates noticeable interference with daily stability.

By working to lower persistently elevated glucose, this insulin contributes to easing the physical symptom burden caused by high sugar. This may assist with managing bothersome symptoms such as excessive thirst, frequent urination, and generalized fatigue that often accompany poor glucose control. Providing this supportive relief may help patients cope more steadily with the day-to-day challenges of diabetes management.

Quick Fact: Supports Functional Stability It is considered relevant for supporting overall metabolic balance and plays a role in managing the risk of long-term diabetic complications linked to persistently high blood sugar.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Humodar B 100?

The population eligibility for Humodar B 100 (Insulin-isophan/NPH) is defined by official regulatory labeling, outlining specific conditions and patient groups for whom the medicine is approved, restricted, or absolutely contraindicated.

---

Contraindicated Populations (Must Not Use)

The medicine is strictly contraindicated and must not be administered in the following circumstances:

• Patients currently experiencing an episode of hypoglycemia (very low blood sugar).
• Individuals with a known severe hypersensitivity or allergy to Insulin-isophan (NPH) or any of the product's components.

---

Approved and Conditional Use

Population Group	Eligibility Status
Adults	Approved for use in patients with Type 1 and Type 2 diabetes.
Pediatric Patients	Approved for use in children and adolescents.
Pregnancy	Permitted. Insulin is the generally preferred treatment for diabetes in pregnant women.
Lactation (Breastfeeding)	Permitted. Use presents no risk to the baby.
Renal/Hepatic Impairment	Requires caution and increased monitoring due to increased risk of hypoglycemia.
Older Adults	Permitted, but may require special consideration due to increased susceptibility to low blood sugar.

Interactions with other medicines and products

The official regulatory interaction profile for Humodar B 100 (Insulin-isophan) is primarily defined by pharmacodynamic effects, where co-administered substances alter the drug's activity in regulating blood glucose. No specific CYP enzyme-mediated or major transporter-based pharmacokinetic interactions that alter the plasma exposure of the insulin component are documented in regulatory labeling.

Substances that Increase the Glucose-Lowering Effect

Certain medicine classes are formally documented to potentiate the effect of Insulin-isophan, which increases the potential for low blood glucose. These categories include Oral Antidiabetic Agents, Angiotensin-Converting Enzyme (ACE) Inhibitors, Salicylates, Monoamine Oxidase Inhibitors (MAOIs), and certain Sulfonamide Antibiotics.

Substances that Decrease the Glucose-Lowering Effect

Conversely, other substance categories are officially noted to counteract the insulin's activity. This counteraction may increase the requirement for insulin and includes Glucocorticoids (Corticosteroids), Thyroid Hormones, Diuretics (e.g., Thiazides), and Sympathomimetic Agents.

Specific Interaction Constraints

• Beta-blockers are officially documented to blunt the warning signs of low blood glucose, which may impact patient recognition of hypoglycemia.
• Co-administration with Thiazolidinediones (TZDs) is officially associated with the risk of dose-related fluid retention and potential exacerbation of heart failure.
• The consumption of alcohol is officially noted to potentially intensify or reduce the glucose-lowering effect of insulin.
• Insulin-isophan is formally restricted from administration during episodes of acute hypoglycemia.

How Humodar В 100 Works

Humodar B 100 acts as an agonist by binding to the Insulin Receptor ( IR), a tyrosine kinase receptor found on the surface of most cells, with high density on muscle and adipose tissue. This binding initiates an intracellular cascade that mobilizes GLUT4 glucose transporters to the cell membrane . This mechanism facilitates the rapid movement of glucose from the bloodstream into these cells, resulting in increased peripheral glucose clearance.

Simultaneously, the drug modulates key metabolic pathways in the liver. It decreases the release of endogenous glucose into the circulation by inhibiting enzymes involved in glycogenolysis (breakdown of stored sugar) and gluconeogenesis (creation of new sugar).

Beyond glucose, the drug promotes anabolism by encouraging the cellular uptake and storage of fatty acids into adipose tissue and amino acids into muscle tissue. These combined actions contribute to modulating overall energy metabolism across major tissue compartments.

How to Use Humodar В 100 (Official Administration Guidelines)

The official instructions for using Humodar В 100, an intermediate-acting recombinant human insulin product, define the method of delivery, dose individualization, and product format required for administration. These requirements ensure the correct and standardized use of the medicine.

Administration Protocol

Guideline Domain	Official Requirement
Route of Administration	Must be administered by subcutaneous injection only.
Official Dosage	The dose and frequency must be determined individually based on the patient's needs and the specifics of their body.
Formulation Type	Suspension for injection, 100 IU/mL concentration.
Product Format	Available in 3 mL cartridges and 10 mL vials (100 IU/ml).

Procedural Structure

Official Step Sequence:

• The patient's therapeutic need must first establish the specific, individualized dose.
• The medicine must be delivered as a suspension for injection (100 IU/mL).
• Administration is strictly via subcutaneous injection using the appropriate device (vial/syringe or cartridge/pen).

Connection to the Overall Use Protocol

These labeled instructions strictly define the medicine's administration via injection into the subcutaneous tissue, confirming the requirement for a parenteral route. The official protocol mandates that the dosage is highly individualized and must be adjusted according to patient-specific data, making dose determination the critical, initial step in its correct use. The instructions specify that the product is a suspension for injection and detail the available commercial formats of the medicine.

Research Evidence / Overview of Studies for Humodar В 100

Evidence for Use in Type 1 Diabetes Mellitus

The research for this insulin's use in Type 1 diabetes includes Randomized Controlled Trials (RCTs) and meta-analyses used to study basal glucose management. These studies were evaluated in adults and children needing insulin replacement. Researchers examined outcomes related to systemic or functional imbalance that were measured during the therapy period, specifically Glycated Hemoglobin (HbA1c), and outcomes describing episodic or acute changes, like the frequency of low blood sugar (hypoglycemia) events.

Findings describe patterns observed in the studies related to HbA1c measurements and patterns of blood glucose stability maintained during fasting periods. Findings were mixed when assessing the precise balance between the measured glucose parameters and the observed incidence of nocturnal hypoglycemia across different comparisons.

It is not yet clear whether the observed effects extend to long-term patient-relevant outcomes, such as major diabetic complications. Furthermore, evidence quality varies across studies.

---

Evidence for Use in Type 2 Diabetes Mellitus

Research examined the use of this insulin in adults with Type 2 diabetes, often when other non-insulin medications alone were insufficient to maintain glucose control. This evidence base includes comparative RCTs and large-scale observational studies. The studies monitored core outcomes, including HbA1c and fasting glucose levels, and tracked the overall incidence of hypoglycemia.

Research highlights changes measured during the study period in the average blood sugar control. Observational data described patterns of how long therapy was continued over time outside of formal trial settings. The studies monitored the incidence of hypoglycemia, noting that the rate and timing was observed in some studies to vary compared to newer basal insulins.

For Type 2 diabetes, follow-up durations were limited in many comparative trials, leaving limited information for long-term outcomes beyond the trial duration.

---

Evidence in Special Populations

Research examined the use of this insulin in children and adolescents with Type 1 diabetes, and pregnant women with various forms of diabetes. The research involves smaller comparative trials that were studied for both maternal outcomes and key fetal/neonatal outcomes.

The sample sizes were modest in many trials focused on pregnant populations. This means the studies often lacked the sample size needed to detect differences in rare, critical fetal outcomes, and certainty remains low for these specific events.

---

What Is Still Uncertain About Humodar В 100 Research

Comparative evidence is lacking in certain areas where trials have not been conducted directly against all available alternatives. Follow-up durations were limited in a significant number of key studies, and long-term outcomes remain an area for further research. Evidence quality varies across studies due to differences in design, and sample sizes were modest in specific populations. Overall, research provides context but not individual predictions.

Key Studies & References NPH Insulin - StatPearls (NIH Bookshelf)

Common questions about Humodar В 100 (FAQ)

Q: What is Humodar В 100 used for?

A: According to the official product information, Humodar В 100 is indicated for the treatment of certain types of bacterial infections. It is generally used to fight infections that have been shown to be sensitive to the active ingredient as determined by regulatory data.

Q: What should I do if I miss a dose of Humodar В 100?

A: Regulatory documents indicate that if a dose is missed, administration should be considered as soon as it is remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose is typically skipped, and the patient continues with the next scheduled dose as planned. Official information advises against taking a double dose to compensate for the missed one.

Q: Can children take Humodar В 100?

A: Official product information indicates that Humodar В 100 can be used in pediatric patients, but the dosage is based on the child’s body weight. The use and dosage for children are determined by a healthcare professional after assessing the specific needs of the patient and the type of infection.

Q: Is it safe to drive or operate machinery after taking Humodar В 100?

A: Studies and official information indicate that Humodar В 100 is not generally expected to impair the ability to drive or use machinery. However, if a patient experiences side effects like dizziness, visual disturbances, or confusion, caution is advised regarding driving or operating machinery until the effects have fully passed.

Official Storage and Disposal Instructions for Humodar B 100

The required storage and disposal conditions for Humodar B 100 are strictly defined by regulatory guidelines to maintain product integrity.

Storage Requirements

Condition	Requirement
Unopened Product	Must be stored in a refrigerator between 2°C and 8°C (36°F and 46°F).
Prohibition	Do not freeze the product; discard if it has been frozen.
In-Use Product	Discard product 28 days after first use. Can be stored at room temperature, not exceeding 30°C (86°F).
Protection	Store in the original container, protected from light and excessive heat.
Child Safety	Keep the product out of the sight and reach of children and pets.

Disposal Instructions

Used needles, syringes, and pen needles must be placed immediately into an FDA-cleared sharps disposal container. Unused, expired, or frozen product must be disposed of according to local pharmaceutical waste regulations or through a drug take-back program. Do not dispose of residual product in household trash or down the drain.